Please assess the completion status of the following clinical trial:

Trial Title: SISTERS: Spasticity In Stroke Study - Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~To be eligible for inclusion into this study, patients must fulfill all of the following criteria prior to study enrollment:~1. patient (or legal guardian) has been informed of the study procedures and has given written informed consent~2. patient experienced last stroke \> 6 months prior to enrollment~3. patient presents spasticity in at least 2 extremities~4. patient presents an Ashworth score ≥ 3 in a minimum of two of the affected muscle groups in the lower extremities~5. patient is eligible to receive ITB Therapy following the Adult Spasticity Algorithm. A patient does not reach his/her therapy goal with other treatment interventions~6. stable blood pressure: no change in hypertensive medication in last month (NOTE: ventriculoperitoneal shunts and valves can be present)~7. if female, she must either be post-menopausal or surgically sterilized; or use a hormonal contraceptive, intrauterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study~8. patient/family is willing to comply with study protocol including attending the study visits~Exclusion criteria:~To be eligible for inclusion in this study the patients must not meet any of the following criteria:~1. patient/family is considered by the physician to be unable or unwilling to participate in long-term ITB Therapy management~2. patient has known hypersensitivity to baclofen~3. active systemic infection (NOTE: pressure sores are not a contraindication unless they are present near the implant sites)~4. presence of a cardiac pacemaker, ICD, implantable neurostimulator or drug delivery device~5. uncontrolled refractory epilepsy~6. use of oral vitamin K antagonists, e.g. warfarin/coumadin; unless the patient can switch to another accepted anticoagulant (e.g. heparin, aggrenox, fragmin, plavix, ticlid) for the period of ITB test and implant~7. patient is pregnant or breastfeeding~8. patient received a Botulinum toxin injection less than 4 months ago

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ITB therapy (Type: ACTIVE_COMPARATOR): Intrathecal Baclofen therapy (Intrathecal baclofen + implantable pump)
- Best Medical Treatment (BMT) (Type: NO_INTERVENTION): Use one or a combination oral antispastic medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).